 | "Each day millions of patients across Europe rely on the supply chain to deliver the medicines they need"Pharmaceutical Distribution in Europe - The Emergence of Direct-to-Pharmacy Supply from URCH Publishing, is a market report that comprehensively reviews the business of medicines distribution in Europe.The traditional model of pharmaceutical supply chain in Europe is under threat as major pharmaceutical manufacturers in the UK attempt to change the way they distribute their products. The adoption of a Direct-to-pharmacy (DTP) model by some of the industry's most powerful players in the UK signifies a new trend that could spread across Europe. |
|
| "Among the 23 new pharmaceutical products approved in the first half of 2007, there were 22 small molecule pharmaceutical drugs and one monoclonal antibody."Pharmaceutical Product Approval Trends 2007: Key market benchmarks and strategic insights presents a detailed analysis of the new pharmaceutical products approved globally.The 120-page report outlines the key therapeutic markets, significant pharmaceutical entities which were approved, assesses major companies and identifies key trends and opportunities in order to help inform pharmaceutical decision-making, particularly in the areas of corporate planning, portfolio management and market forecasting. |
|
| For many years generic companies were the poor relations of the pharmaceutical industry, with modest growth rates and little or no transnational business operations. As generics companies have grown, often by acquisition, they have generally developed as international businesses. |
|
| "The global pharmaceutical market grew to US$643 billion in 2006, growing at a compound annual growth rate (CAGR) of 10.0% between 1999 and 2006. However, year-on-year growth slowed to 6.8% in 2006, largely as a result of increased competition from generic products and the effects of continued healthcare cost containment across major markets." |
|
| The global cardiovascular market is forecast to expand to US$116.3 billion in 2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in cardiovascular market growth between 2003 and 2005 is forecast to continue through to 2010. While continued changes in demographics and lifestyle will continue to drive cardiovascular sales forward, growth rates will be limited by continued patent expiries for major products and a dearth of novel therapies being introduced.Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for cardiovascular disorders including: - Coronary heart disease- Cerebrovascular disease - Peripheral arterial disease- Rheumatic heart disease - Congenital heart disease- Deep vein thrombosis and pulmonary embolism This comprehensive report, from URCH Publishing, delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making. |
|
| The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%.Between 2003 and 2005, global CNS sales increased by 19% and accounted for 9.2% of total global pharmaceutical sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to 6.6% in 2005 as a result of generic competition for leading anti-depressant and epilepsy therapies. |
|
| The Handbook of Pharmaceutical Additives, 3rd Edition describes more than 5,300 trade name products and 4,000 generic chemicals and materials, available from worldwide manufacturers, that function as pharmaceutical additives. |
|
| “The period 2007 to 2011 will see the expiration of patent protection for 52 major drugs in the United States, an average of ten a year. With 2005 seeing a decline in the number of NCEs approved down to 18 from 23 in 2004, there is clear evidence that the loss of revenue from patent protected drugs will impact upon the growth of the industry when so few new drugs are reaching the market.“ |
|
| The global cancer market has just seen a period of rapid growth. Between 2003 and 2005, global sales for cancer treating drugs increased by 40% and now account for more than eight percent of total global pharmaceutical sales. Although growth rates for this market will slow due to generic competition the market is predicted to expand to $85.3 billion by 2010 equivalent to CAGR of 11.1% |
|
